Elevated SOX11 mRNA level correlates with favorable prognosis in mantle cell lymphoma.
To explore the prognostic value of SOX11 in patients with mantle cell lymphoma (MCL). The clinical data and paraffin-embedded tissue of 75 primary MCL in Shanxi Tumor Hospital were collected, and the MCL international prognostic index (MIPI) was rechecked in all cases according to simplified (sMIPI) formula. The expression of SOX11 mRNA was detected by reverse transcriptase-polymerase chain reaction (RT-PCR) and the relationship of survival with SOX11 mRNA and MIPI in MCL patients was evaluated. Median survival was 44 months in cases with low-risk, 31 months in cases with intermediate-risk and 30 months in cases with high-risk. There was statistically significant difference between low-risk and high-risk group (p=0.0033), while there was no statistical difference between low-risk group and intermediate-risk group (p=0.1067) and the intermediate-risk group and high-risk group (p=0.6149). Furthermore, cases were divided into group SOX11mRNA<M (median of SOX11 mRNA level) and group SOX11mRNA≥M in each MIPI group according to SOX11 mRNA expression, and the results of 3 groups all showed that median survival was shorter in group SOX11mRNA<M than that in SOX11mRNA≥M (p<0.05). Univariate analysis showed poorer survival was associated with blastoid transformation, ECOG≥2, p53 positive, bone marrow involvement, high-risk group and SOX11mRNA<M. Multivariate analysis showed blastoid transformation, high-risk group and SOX11mRNA<M were poor prognostic factors. SOX11 mRNA level has certain prognostic value and SOX11 mRNA≥M was related to good prognosis.